menu search

ALKS / Here's Why You Should Add Alkermes (ALKS) to Your Portfolio

Here's Why You Should Add Alkermes (ALKS) to Your Portfolio
Alkermes (ALKS), a top-ranked stock, has a diverse portfolio of neurological therapies. Its proprietary products are witnessing incremental sales. Read More
Posted: Jul 4 2023, 09:14
Author Name: Zacks Investment Research
Views: 1031100

ALKS News  

Alkermes (ALKS) Down Despite Q3 Earnings & Revenue Beat

By Zacks Investment Research
October 26, 2023

Alkermes (ALKS) Down Despite Q3 Earnings & Revenue Beat

Alkermes' (ALKS) earnings and revenues trump estimates in the third quarter of 2023. The company reiterates total revenue guidance for full-year 2023. more_horizontal

Why Alkermes Stock Is Sinking Today

By The Motley Fool
October 25, 2023

Why Alkermes Stock Is Sinking Today

Alkermes' third-quarter results beat Wall Street's expectations. However, investors appeared to still be disappointed with a clinical update announced more_horizontal

Alkermes Plummets In Huge Volume. Why One Analyst Says The Reaction Is Overdone.

By Investors Business Daily
October 23, 2023

Alkermes Plummets In Huge Volume. Why One Analyst Says The Reaction Is Overdone.

Alkermes stock plummeted to its lowest price since last December on disappointing test results for its experimental narcolepsy treatment. more_horizontal

Alkermes (ALKS) Recently Broke Out Above the 50-Day Moving Average

By Zacks Investment Research
September 7, 2023

Alkermes (ALKS) Recently Broke Out Above the 50-Day Moving Average

Alkermes (ALKS) reached a significant support level, and could be a good pick for investors from a technical perspective. Recently, ALKS broke through more_horizontal

Alkermes (ALKS) Grants Teva License to Market Generic Drug

By Zacks Investment Research
August 31, 2023

Alkermes (ALKS) Grants Teva License to Market Generic Drug

Alkermes (ALKS) grants Teva an exclusive license to market a generic version of Vivitrol in the United States, thereby resolving patent litigation. Th more_horizontal

Alkermes shares surge after settlement with Teva on alcohol dependence treatment

By Market Watch
August 30, 2023

Alkermes shares surge after settlement with Teva on alcohol dependence treatment

Shares of Alkermes PLC ALKS, +9.68% jumped 10% Wednesday after the Dublin-based biopharma company announced a settlement of patent litigation with Tev more_horizontal

Lybalvi: Weighing In Light, But Tipping Alkermes' Scales

By Seeking Alpha
August 24, 2023

Lybalvi: Weighing In Light, But Tipping Alkermes' Scales

Alkermes to split neuroscience and oncology divisions; strong growth with drug Lybalvi highlighted. Financials show robust growth; concerns include a more_horizontal

Alkermes plc (ALKS) Q2 2023 Earnings Call Transcript

By Seeking Alpha
July 26, 2023

Alkermes plc (ALKS) Q2 2023 Earnings Call Transcript

Alkermes plc (NASDAQ:ALKS ) Q2 2023 Earnings Conference Call July 26, 2023 8:00 AM ET Company Participants Sandra Coombs – Senior Vice President-Cor more_horizontal


Search within

Pages Search Results: